Immunotoxin fusion proteins and means for expression thereof
The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.
1. A nucleic acid encoding an anti-T cell immunotoxin fusion protein, comprising, from the amino terminus, a truncated diphtheria toxin moiety, a connector, and two single chain Fvs of the variable region of a UCHT1 antibody, wherein the two single chain Fvs comprise VL, L, VH, L, VL, L, VH, wherein L is a Gly-Ser linker, wherein the diphtheria toxin moiety contains the first 390 amino acids of the native toxin, wherein VL and VH are the variable light and heavy domains of the anti-CD3 antibody UCHT1, and wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO:30.
2. A nucleic acid encoding an anti-T cell immunotoxin fusion protein, comprising, from the amino terminus, a truncated diphtheria toxin moiety, a connector, and two single chain Fvs of the variable region of a UCHT1 antibody, wherein the two single chain Fvs comprise VL, L, VH, L, VL, L, VH, wherein L is a Gly-Ser linker, wherein the diphtheria toxin moiety contains the first 390 amino acids of the native toxin, wherein VL and VH are the variable light and heavy domains of the anti-CD3 antibody UCHT1, and wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 102.